ISSUE 8/2025

BDMAI BULLETIN

From the Desk of President

Dear Friends,

To hold on to our stronghold in the ever-evolving global pharmaceutical landscape, the need for sustainable development in the Indian API industry has never been more pressing than it is today. While we continue to strengthen our capabilities, external headwinds—such as the emerging U.S. tariff measures on pharmaceutical imports—serve as a timely reminder that agility and preparedness must be central to our growth strategy.

This situation can be viewed in two ways – One approach is to assume such measures will primarily impact importers, causing only a short-term dip in the profitability of Indian players—and move on. The other, more strategic path is to proactively strengthen our industry's foundation—ensuring compliance with international drug regulations, environmental laws, and global quality expectations—so that we can withstand and thrive amid future external shocks.

At the heart of this evolution lie three critical pillars – R&D, Digital Transformation and Green Chemistry. Our industry has long recognized the importance of R&D and innovating cost-effective synthesis routes. However, Digital Transformation—a relatively new but vital concept—must now be embraced seriously by all stakeholders. Most critically, Green Chemistry has become the need of the hour.

It is time for the industry to look at Green Chemistry not just as a regulatory requirement, but as a strategic advantage. It offers improved cost-efficiency and global competitiveness. Designing safer synthesis routes, implementing efficient solvent recovery and recycling, reducing waste, conserving water, and adopting cleaner production technologies etc., have become immediate imperatives. In the coming months, BDMAI will organize seminars, expert sessions, and share information about advanced technologies to our members to accelerate the adoption of Green Chemistry.

With Warm regards

R K Agrawal
National President, BDMAI

In this Bulletin you can expect

Global Pharma News

MOUs/JVs:

Niagen Bioscience signs exclusive licence deal for PD therapy

Niagen Bioscience can either commercialise the drug candidate independently or sublicense to a strategic pharmaceutical partner. Niagen Bioscience has secured a worldwide exclusive commercial licence agreement with Haukeland University Hospital, Bergen, Norway, for the development of a treatment for Parkinson's disease (PD). The agreement grants Niagen Bioscience exclusive rights to proprietary intellectual property, know-how and data, critical for future regulatory filings in the European Union under European Medicines Agency guidelines for the potential treatment of PD using its patented nicotinamide riboside (Niagen) molecule.

Pharmaceutical Technologies 9.7.2025

AstraZeneca and Revna Biosciences Expand Lung Cancer Treatment Access in Ghana

Since announcing their partnership in April 2025, AstraZeneca and Revna Biosciences have made significant strides in improving lung cancer care across Ghana, from early diagnosis to access to advanced targeted treatments. A major milestone was reached with the launch of AstraZeneca's targeted therapy for patients with EGFR-mutated lung cancer, marking a critical step in bringing cutting-edge treatments to sub-Saharan Africa.

Pharma Journalist 31.7.2025

M & As

MSD acquisition to accelerate first-in-class COPD drug

The $10 billion acquisition involves advancement of a novel inhaled therapy which has potential to redefine standard of care in respiratory disease. MSD, through a subsidiary, has agreed to acquire Verona Pharma for a total of approximately $10 billion. Through this deal, MSD will gain rights to ohtuvayre® (ensifentrine), a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4).

European Pharmaceutical manufacture – 10.7.2025

Sino Biopharma spends $951m to acquire China-based LaNova Medicines

Both AstraZeneca and MSD have secured lucrative licensing deals for two of LaNova's oncology assets in recent years. Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing one of the largest transactions within the Asia-Pacific pharmaceutical arena this year. Sino already owns a 4.91% stake courtesy of an investment in November 2024, with the company now seeking to purchase the remaining 95.09% it does not own. At the time, Sino spent 142 million yuan ($19.80m) to initiate its ownership involvement with the biotech.

Pharmaceutical Technologies 15.7.2025

Boehringer partnership to advance biologic for rare skin condition

The new partnership between Boehringer Ingelheim and LEO Pharma aims to expand treatment access for more patients with generalised pustular psoriasis. Boehringer Ingelheim and LEO Pharma have agreed a partnership deal to advance development and commercialisation of the innovative monoclonal antibody Spevigo. Boehringer Ingelheim is set to receive €90 million upfront as part of the agreement. This is in addition to milestone payments and royalties. LEO Pharma will commercialise and further develop the monoclonal antibody. The new facility will manufacture peptides, small molecules and oligonucleotides.

European Pharmaceutical review 19.7.2025

Sanofi $1.6 billion acquisition to advance respiratory vaccines

The new deal could support innovation of next-generation combination vaccines to protect older adults against multiple respiratory viruses. Sanofi has agreed to acquire the biotech Vicebio for an upfront payment of $1.15 billion, supporting the advancement of respiratory virus vaccines. In addition to the initial payment, Sanofi will pay up to $450 million, subject to achieved development and regulatory milestones. The deal intends to expand capabilities in vaccine design and development and will enable Sanofi to add a non-mRNA vaccine to its development pipeline.

European Pharmaceutical review 23.5.2025

Drug Approvals:

FDA Approves Insulin Aspart-Xjhz as First Interchangeable Biosimilar to NovoLog

The FDA approved insulin aspart-xjhz (Kirsty) 100 units/mL as the first and only interchangeable biosimilar to insulin aspart (NovoLog). The biosimilar, a rapid-acting human insulin analog, is indicated for glycemic control in adults and pediatric patients with diabetes.

Drug Topics 20.7.2025

Agios' PYRUKYND (Mitapivat) Approved in Saudi Arabia for Adult Thalassemia Patients

Agios Pharmaceuticals, Inc. announced that the Saudi Food and Drug Authority (SFDA) has approved PYRUKYND (mitapivat) for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.

Pharma Journalist 4.8.2025

Teva's Ajovy becomes first migraine prevention drug approved for children

With the label expansion, Teva gains an edge over rivals Amgen and Eli Lilly in the CGRP inhibitor arena. The US Food and Drug Administration (FDA) has approved a label expansion to Teva's Ajovy in certain children and adolescents, making it the first migraine prevention drug of its kind in the age group. Single-dose injectable Ajovy (fremanezumab-vfrm) is now approved for the preventive treatment of episodic migraine in children and adolescent patients aged between six and 17 years who weigh 45kg or more.

Pharma Journalist 4.8.2025

Investments:

AstraZeneca announces $50bn US investment plans by 2030

AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing, and research and development (R&D). The investment represents a substantial capital infusion to the $3.5bn announced in November 2024. The focus of this investment is a manufacturing facility dedicated to producing drug substances for AstraZeneca's weight management and metabolic product range. The new facility will manufacture peptides, small molecules and oligonucleotides.

Pharmaceutical manufacturer 23.7.2025

DRUG DEVELOPMENTS:

4TEEN4 begins trial of antibody therapy for cardiogenic shock

4TEEN4 Pharmaceuticals has dosed the first patient in a phase 1b/2a trial of procizumab, a monoclonal antibody designed to treat cardiogenic shock by neutralising a key biological driver of the condition. The multicentre PROCARD1 trial will assess safety, dosing and early signs of efficacy in up to 70 patients with elevated levels of circulating dipeptidyl peptidase 3 (cDPP3), a cardiac depression factor linked to poor outcomes in shock.

Pharma Times 23.7.2023

Eli Lilly's Mounjaro shows cardiovascular gains, but analysts underwhelmed

Eli Lilly's trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations. A trial investigating the ability of Eli Lilly's Mounjaro (tirzepatide) to reduce the risk of cardiovascular issues has met its endpoints, though analysts were left underwhelmed by the degree of efficacy. Eli Lilly is attempting to join fellow pharma companies with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) – drugs originally approved for treating diabetes – gaining expanded label expansions in cardiovascular indications.

Pharmaceutical Technologies 1.8.2025

Glipizide Increases Cardiovascular Risk Compared With DPP4 Inhibitors in T2D

Sulfonylureas were associated with an increased risk of cardiovascular events in patients with type 2 diabetes (T2D) compared to dipeptidyl peptidase 4 (DPP4) inhibitors, according to data published in *JAMA Network Open*.[1] The study, which found the risk was highest for glipizide, suggests sulfonylureas may not be the best choice of medication for patients with T2D who have moderate cardiovascular disease risk.

Drug Topics 5.8.2025

General Pharma News:

Law to Decentralize Personalized Drug Manufacturing in UK

This recent legislation, which has been passed, which is the Human Medicine Regulations 2025, goes on to make the UK the first country throughout the world to come up with a dedicated legal framework when it comes to medicines that are to be made at the point of care. Presented by the Medicines and Healthcare Products Regulatory Agency (MHRA), it will help the patients to get personalized treatments made at their hospitals, clinics, or even nearby their homes. Therapies are at present manufactured in laboratories, which happens to extend the vein-to-vein timeframe because of shipping needs.

World Pharma today 27.7.2025

HS market forecast to reach $7.8bn across 7MM by 2034

This 15.6% CAGR is largely attributed to the launch of novel biologics and small molecules. The hidradenitis suppurativa (HS) market across the seven major pharmaceutical markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is forecast to grow from $1.84bn in 2024 to $7.83bn in 2034, according to GlobalData. This 15.6% compound annual growth rate (CAGR) is largely attributed to the launch of novel biologics and small molecules targeting multiple inflammatory pathways beyond TNF-alpha inhibition.

Global Data Healthcare 28.7.2025

South Korea emerges as 2025 licensing hub with 113% growth and billion-dollar deals

Key transactions this year emphasise the global demand for Korean biopharma innovation. South Korea's biopharmaceutical sector has seen a surge in innovator drug licensing agreements, reaching a total deal value of $7.86bn in 2025 year-to-date (YTD), at a 113% increase from 2024, according to GlobalData's Pharmaceutical Intelligence Center Deals Database. This recovery is driven by billion-dollar agreements with large pharma companies such as Eli Lilly and GSK, and follows a dip to $3.67bn last year due to broader macroeconomic challenges.

Global data healthcare 29.7.2025

Association Activities

New System for issue of WHO-GMPs

CDSCO issued a circular on 25th June 2025 informing the industries that a new online system will come into effect from 15.7.2025 for issue of WHO GMP (CoPPs) and no application in hard copies will be accepted. Since this sudden transition to a new system without will cause lot of disturbance to the exports, BDMAI immediately wrote a letter DCI requesting them to organize awareness meetings about the new system and also to continue to accept off-line applications for some time. In response, CDSCO organized a demo session on 10th July, during which many members expressed that the system is too complicated.

CDSCO extended the date of implementation of new system to 15th August 2025. Further, Zonal office, Hyderabad organized four interactive meetings for the benefit of members, both online and offline. As there are no applications being filed online, Zonal office of CDSCO wanted to understand actual problems faced by the Industry. BDMAI organized a meeting on 1st August 2025, where 20 representatives of various companies attended. Issues raised in the meeting were compiled and submitted along with BDMAI recommendations to CDSCO Zonal office. Please click here for detailed representation.

Bulk Drug Park, Himachal Pradesh

A Bulk Drug Park is being established in the State of Himachal Pradesh. To invite investments in their Park, senior officials of Industries department of Himachal Pradesh organized an Investor Meet on 10th July 2025 at Hyderabad. Some of the members participated and interacted with them.

ET Pharma Tech Innovate Conclave

ET Pharma Tech Innovate Conclave was organized by ET Pharma on 11th July 2025 at Hyderabad, where the President, BDMAI was one of the panelists in a Panel discussion. The primary aim of the Conclave is to explore how digital technologies, such as Pharma 4.0, block chain, and cyber security, transforming drug development, regulatory compliance, and supply chains for faster and more efficient market access.

Employment linked Incentive Scheme:

Department of Pharmaceutical organized an online meeting on 14th July 2025 to explain about Employment Linked Incentive Scheme, which is being implemented by EPFO with effect from 1st August 2025. The objective of the scheme is to incentivize additional employment in formal sectors. Under this scheme:

-Employees (first timers only) with a monthly gross salary of less than Rs. 1.00 lac will get one-time incentive of Rs. 15,000/-

-Employers will get 10% of gross salary for every additional employment. To get this benefit, there should be an additional employment of at least 2 persons (for a company with less than 50 employees) and 5 persons (for a company with more than 50 employees). These additional employees can be first timers or re-joiners

-The scheme will be applicable for 4 (four) years for manufacturing companies and 2(two) years for other establishments

Detailed presentation has been uploaded in our website. Please click here to download the same.

Lean Management Practices

Quality Control Forum, which is an implement agency of QCI and MSME schemes, is entrusted with empowering MSMEs through Lean Management Practices. They are conducting an awareness programme on 25th July 2025, where members are can register themselves for the 6 months training programme. A circular has been sent to members on this subject, copy of which is enclosed

Online Session on 'Powder Safety in Process Industries (Dust Cloud Explosion)

Council of EHS Professionals (CEP) is organizing an online Session on Powder Safety in Process industries (Dust Cloud Explosion on 26.7.2025. BDMAI circulated the same to the members. Many members participated in the meeting and got benefited.

Representations

Minimum Wages in Telangana

BDMAI received a communication from the Joint Director of Industries department seeking comments from the industry on the recommendations made by the Committee for Minimum Wages in Telangana. In response, BDMAI submitted its comments / inputs. Please click here to see the comments given by BDMAI

Women employment in Hazardous areas:

Recently all Telangana State Government revoked the prohibition of women employment in Hazardous areas. FTCCI sought industry inputs on the impact of this decision. BDMAI submitted its inputs. Please click here to see the response given by BDMAI

Plastic Waste Management Rules 2025

Ministry of Environment, Forest and Climate Change issued a notification on 3rd June 2025 notifying the plastic Waste management Draft Rules 2025. As per the Rules all industries are required to use only re-cycled plastic for their 60-80% of their total requirement. BDMAI represented to MoEF seeking exemption for our Industry, as the industry is required to comply with GMP Regulations. Please click here for copy of our representation.

Notifications

Online system for NoC for dual usage:

CDSCO issued a Circular notifying that a new online system is available on SUGAM portal for applying NoC for Dual usage of drugs imported in bulk. Click HERE for the circular.

Ranitidine:

CDSCO issued a public notice about safety of Ranitidine due to presence of NDMA purity. Please click HERE for the notification

MOOWR Scheme:

Online application facility will continue to be on Invest India Portal till October 2025. Please click HERE for complete circular issued by CBIC

Fixation of SIONs

DGFT issued a notification fixing SIONs for Betamethasone, Ferruous Fumerate (from two different import products). Please click HERE for a detailed circular.

Scaling up Green Chemistry Principles for Pharma Manufacturing

European Pharmaceutical Manufacturer 18 July 2025

New environmental regulations and increasing consumer demand for corporate sustainability drive pharmaceutical companies to commit to green chemistry processes. Ellie Gabel, associate editor for Revolutionized discusses.

Scaling up ecologically sound principles is no longer an option but a strategic priority to reduce waste, energy, and harmful substances during medicine manufacturing.

Current state of green chemistry adoption in European pharma

Green chemistry adoption is growing exponentially, with over 60 known instances of pharmaceutical entities implementing it in research and manufacturing. The shift toward sustainable drug design and development aims to reduce or eradicate toxic chemicals, focusing on ecological safety and efficiency.

Of the 65 to 100 million kilograms of polluting active pharmaceutical ingredients (APIs) produced annually, 10 billion kilograms of waste have been generated. Pharma is also responsible for 17% of global carbon emissions, half of which derives from APIs. An impressive 75% of pharmaceutical brands have reshaped their business models to account for Climate Scenario Analyses, which help them assess risks and create more resilient strategies for sustainability.

The European Green Deal is among the most significant green pharmaceutical innovation and manufacturing incentives. The policy initiatives are pushing for carbon neutrality by 2050 across the European Union. Other incentives include the Regulation on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), the Strategic Approach to Pharmaceuticals in the Environment, and enterprises' individual goals to achieve net-zero emissions.

Core green chemistry principles and their application at scale

In 1998, American scientists John Warner and Paul Anastas developed the 12 principles of green chemistry. Pharmaceutical companies still apply this framework to decrease the environmental impact of chemical processes through waste reduction, safer medicinal designs, less hazardous substances and solvents, and energy efficiency, among other actions.

These directions are especially crucial in commercial manufacturing, where businesses aim to eliminate waste and optimise recycling. Replacing dangerous solvents with water, bio-based solvents and other green alternatives is also gaining traction.

Additionally, manufacturers use microwave-assisted synthesis to lower energy consumption. The process enables a chemical reaction within minutes through electromagnetic radiation, ionic conduction and dipole polarisation, helping pharmaceutical producers save time and energy.

Technological innovations enabling scale-up

Many technologies already exist to eliminate harmful pharmaceuticals from the environment. For instance, granular activated carbon and nanocellulose filters enable wastewater treatment plants to absorb pollutants more effectively. Bioremediation — using plants and microbes to remove APIs — is also practical. Algal species like Chlamydomonas acidophila, in particular, can collect and degrade some medicines.

However, new developments aim to stop pharmaceutical waste before it leaves the manufacturing plant. Some technological methods include the following:

- **Continuous flow synthesis:** Utilises specialised equipment to improve management of and optimise reactions in pharmaceutical production
- **Analytical techniques:** Minimises and eliminates chemical toxicity in laboratories through green chromatography, spectroscopy, and bioassays

The deployment of AI and machine learning solutions in green chemistry processes also helps synthesise large datasets, reduce human error, and predict reaction conditions, further accelerating innovation and utilising sustainable manufacturing practices.

What's next for green chemistry in pharma?

The future of green chemistry in the pharmaceutical industry will likely concentrate on building a circular economy to reduce waste and optimise resource use. Developing green APIs will help reduce the detrimental impacts on ecosystems and public health. A long-term strategy entails creating non-synthetic APIs with fewer adverse effects.

Pharmaceutical manufacturers are also exploring digital twins technology for internal tracking and training, despite hesitation in implementing a digital shadow for two-directional information exchange. Nevertheless, drug manufacturers can use the technology when designing more sustainable medicines with considerations for end-of-life recycling.

Green pharmaceuticals is the future

Scaling up green chemistry in the pharmaceutical industry is crucial for protecting the planet and people. As the sector transforms its manufacturing processes to adhere to sustainability regulations, brands no longer have a choice in whether to commit to improving the environment individually.

Success Formula for Building Strategic Partnerships

Dr. Ajay Babu Pazhayattil

Often, the diligent efforts of the scientists and professionals employed at bulk drug manufacturing organizations are overlooked. Just like front-line health professionals, the bulk drug manufacturing industry plays a critical role in making drugs available on time in full, enabling formulation and new product launches. Here we discuss how drug product owners, clients, and purchasers can work together with bulk drug manufacturers to continue moving down the path of successful delivery of the end product, lifesaving medications.

Proven Success Formula

A market survey [1] has identified the following simple attributes as the top factors for choosing a partner manufacturing organization:

- Regulatory compliance
- Awareness of customer requirements
- Segment experience
- Industry reputation
- Cost
- Assurance on safeguarding IP

Post-engagement, the following additional attributes become essential as well:

- Transparency
- Responsiveness
- Meeting delivery commitments.

Well-informed organizations can put in efforts to go above and beyond these expectations. Employing transparency/integrity-enhancing technologies and hearing out customer requirements are priorities. Blinding processes and protocols are available for organizations to ensure the proprietary data privacy and security. Maintaining a steadfast reputation in the industry is achieved through industry organization involvement and quality publications. Competitive costing is becoming commonplace, requiring an agile costing model and providing alternate options [2]. Differentiating and offering value-added services, developing payment models, and providing dedicated client support are the other focused activities that can be introduced. The US FDA has recommended metrics such as lot acceptance rate (LAR), product quality complaint rate (PQCR), and invalidated out-of-specification rate (IOOSR) with the publication of the draft quality metrics guidance [3]. Whether the FDA intends to make reporting mandatory and publish them, similar metrics can now be mandated by clients. Organizations, in order to successfully meet similar metrics, are obligated to maintain a quality culture, high compliance, and integrity. Checks and balances to minimize compliance risks, operational excellence, and strategies to maintain high service levels are in-built traits of successful organizations targeting high facility EBITDA.

True Partnership

A bulk drug manufacturer provides products and manufacturing services amid varying levels of customer expectations. The clients can range from resellers, clinical, to commercial-level formulation organizations. To be effective, the client point of contact

must be aware of the multi-client, multi-product operational circumstances of a manufacturing organization. Constantly being cognizant of the boundaries goes a long way in solidifying a relationship. In case of CMO type partnerships, the manufacturing organization generally allocates project hours to a specific project activity. Hence, pre-planning sessions can be effective in improving understanding and the efficiency of knowledge transfer activities, where required. Agreements need to establish the onsite visits/audits and their scope.

Adding layers of compliance monitoring can disrupt operational efficiency at the manufacturing site. It needs to be understood that a facility receives a large number of pre-engagement and routine audits in addition to the mandated regulatory audits. Instead of having frequent audits, a full-time person-in-plant who can provide side-by-side support during critical phases of a project may be an ideal solution.

It is essential to establish an incentive plan as soon as a bulk drug manufacturing partner organization is engaged. Organizations that consistently deliver high-quality products, meet established deadlines, and respond promptly need to be significantly rewarded with more autonomy. This can lead to further excellence, ultimately benefiting the products and services provided. Client organizations increasingly use consultants for vendor management, which can cause an added layer of complexity. In cases where more parties are involved, the delivery timeline metric should be carefully monitored so that the actual delay factors are captured.

Bulk drug manufacturing segment provides an excellent opportunity for its employees to gain valuable experience with the diverse projects. The fast-paced nature of the industry develops subject matter experts. However, they have a minimal chance to reflect on how their contributions helped bring critical medicines to the market. Presentation sessions providing final product insights and direct-to-partner organization gratitude events at the manufacturing sites will be highly appreciated by the employees and management.

A lot of planning goes into making a single batch. For instance, it includes timely sourcing of raw materials, components, reactor scheduling, storage, cleaning, documentation, training, resource planning, utility, calibration, qualification, safety, transfers, manufacturing, sampling, analysis, packaging, storage, waste management. Since aligning the activities and executing the manufacturing steps involves meticulous coordination, swift batch injections and last-minute change requests can affect the operational performance level and revenue of the entire facility.

Organizations develop standard operating procedures that are fit for the facility activities, and they may not always align with client procedures. The procedures are, however, designed to meet regulatory and general client expectations. Client-specific procedures for general activities may be developed if necessary; however, this comes with the risk of failure to execute, especially if the execution is non-routine.

When required, the client technical team's hands-on involvement during brainstorming and root cause analysis is undoubtedly an advantage. While the manufacturing site

leads the investigation, any support, such as statistical data analysis, external testing, etc., may be provided to accelerate investigation completion and establish the findings. In case of needing additional testing or time for investigations, providing the manufacturing partner with a batch order for a non-impacted process/product will be desirable.

Just like monitoring a manufacturing partner's performance, it is also vital for the client to gauge the performance of the client's internal point of contact. The source data for such assessments should be routinely (anonymously) sourced from the manufacturing partner. Special attention may be given to aspects such as the expertise level on the activities performed, responsiveness, input and collaboration, cycle time, and engagement etiquette. Such data can help in developing and maintaining an effective vendor management team.

Summary

Developing a cordial give-and-take relationship with the bulk drug manufacturing partner's quality team is critical [4]. Continually communicating the importance and value of the product manufactured at the site and building employee ownership in the product and process has been seen to be effective. Acknowledgement of the fact that each bulk drug manufacturer maintains diverse lifesaving products and diverse clientele will lead to developing approaches that support their operating model. Rather than taking non-issue partner organizations for granted, developing incentives for good performers can only create a special affinity and encouragement to maintain high service levels.

References:

1. *Pharma's Almanac: Changes in the Wind for the CDMO Market:* https://www.pharmasalmanac.com/articles/changes-in-the-wind-for-the-cdmo-market
2. *Journal of Generic Medicines: A Novel Development and Portfolio Management Strategy for Generic Small Molecule Drug Products: Watergile ANDA:* https://journals.sagepub.com/doi/10.1177/1741134320918339
3. *FDA: Quality Metrics for Drug Manufacturing:* https://www.fda.gov/drugs/pharmaceutical-quality-resources/quality-metrics-drug-manufacturing
4. *A Better Path for CMO Relationships, CMO Leadership Awards:* https://www.qqdigitalpublishing.com/publication/?m=53489&i=737164&p=18&ver=html5

India's Export of Bulk Drugs - May 2025

S.No.	HSCode	Commodity	May-2024 (F)	May-2025 (F)	%Growth	Apr-May24 (F)	Apr-May25 (F)	%Growth
1	17023010	GLUCOSE LIQUID	45.15	41.45	-8.18	89.34	77.38	-13.38
2	17023020	GLUCOSE SOLID	8.98	6.64	-25.98	14.83	12.54	-15.48
3	17023031	DEXTROSE,SOLID	9.87	15.95	61.63	18.91	28.76	52.10
4	17023039	DEXTROSE OTHER THAN SOLID	0.29	0.65	125.05	0.92	1.14	23.87
6	17024039	DEXTROSE OTHER THAN SOLID	0.01	0.01	-19.47	0.62	0.34	-44.60
7	29051410	ETHAMBUTOL, ETHAMBUTOL HCL	6.77	1.51	-77.64	9.50	6.53	-31.31
8	29051420	SALBUTAMOL SULPHATE	6.38	4.97	-22.16	16.97	13.53	-20.31
9	29054300	MANNITOL	3.39	3.22	-4.98	10.38	10.17	-2.10
10	29054400	D-GLUCITOL (SORBITOL)	38.95	50.33	29.19	77.90	98.86	26.91
12	29071930	THYMOL	8.23	4.83	-41.28	12.07	10.40	-13.89
13	29072200	HYDROQUINONE (QUINOL) AND	7.08	10.51	48.35	12.29	17.38	41.37
14	29095010	GUAIACOL	1.94	1.33	-31.09	3.22	2.56	-20.36
16	29124940	3,4,5-TRIMETHOXY-	1.20	3.48	191.17	2.67	3.48	30.49
17	29154010	MONOCHLOROACETIC ACID,THR SALTS AND ESTERS	9.57	11.96	24.96	17.16	20.19	17.67
18	29163120	BENZYL BENZOATE	3.33	2.55	-23.49	5.82	5.65	-2.81
19	29163150	BENZOCAINE (ETHYLPARA-AMINO	2.38	1.44	-39.66	4.23	3.20	-24.33
20	29163400	PHENYLACETIC ACID AND ITS SALTS	0.83	0.74	-10.50	1.74	2.60	49.48
21	29171940	FERROUS FUMERATE	5.93	5.11	-13.78	10.22	11.53	12.76
22	29171970	ETH0XY METHYLENE MAL0NATE,DIETHYL MAL0NATE	0.01	1.20	######	0.01	1.22	########
23	29181120	CALCIUM LACTATE	0.25	0.06	-75.54	0.29	0.21	-26.80
24	29181320	METROPROLOL TARTRATE	7.44	6.61	-11.18	16.57	14.21	-14.25
25	29181510	POTASSIUM CITRATE	3.88	1.08	-72.08	7.42	5.59	-24.65
26	29181520	SODIUM CITRATE	6.48	13.51	108.57	21.30	23.43	10.00
27	29181550	FERRIC AMMONIUM CITRATE	1.00	0.40	-60.40	1.32	1.06	-20.10
28	29181610	CALCIUM GLUCONATE	6.73	7.06	4.88	10.09	8.66	-14.19
29	29181620	FERROUS GLUCONATE	1.18	0.04	-96.48	1.35	0.68	-49.33
30	29182110	SALICYLIC ACID	0.96	1.85	93.11	2.90	3.64	25.78
31	29182120	SODIUM SALICYLATE	3.38	1.27	-62.29	5.21	3.47	-33.52
32	29182200	0-ACETYLSALICYLIC ACID ITS SALTS	2.69	0.52	-80.76	3.28	2.77	-15.77
33	29182310	METHYL SALICYLATE	6.57	5.93	-9.72	11.72	10.93	-6.77
34	29182320	AMINO SALICYLATE	0.71			0.71	0.99	39.73
35	29183030	NALIDIXIC ACID	0.10	0.56	493.80	0.13	0.92	612.55
37	29199030	IRON GLYCEROPHOSPHATE	0.01	0.01	187.33	0.01	0.03	543.47
38	29214236	METHYL DOPA(L-ALPHA METHYL-3, 4-DIHYDROXYPHENYLALANINE)	0.05			0.05	0.20	274.49
39	29214600	AMFETAMINE BENZFETAMINE ETC	25.22	83.12	229.52	27.20	127.29	367.91
40	29215110	O- PHENYLENEDIAMINE	1.53	0.94	-38.43	1.85	2.11	14.50
41	29215120	M-PHENYLENEDIAMINE (M-DIAMINOBENZENE)	6.23	23.93	284.40	9.86	43.54	341.42
42	29215130	P-PHENYLENEDIAMINE	7.95	12.04	51.45	17.64	19.03	7.88
43	29215170	PARA-AMINO ACETANILIDE	0.29	0.61	106.45	0.31	1.21	284.73
46	29223100	AMFEPRA NONE(INN), METHDONE AND	0.32	1.13	253.22	0.32	1.13	253.22

47	29224100	LYSINE AND ITS ESTERS SALTS	0.68	1.35	98.18	0.85	2.74	220.97
48	29224210	GLUTAMIC ACID	0.02	0.35	######	0.15	0.36	129.81
49	29224220	MONOSODIUM GLUTAMATE	0.23	0.39	67.34	1.06	0.88	-17.16
50	29224400	TILIDINE (INN) AND ITS SALTS	0.25			0.25		
51	29224910	AMINO ACETIC ACID (GLYCINE)	11.40	17.43	52.94	24.57	36.66	49.21
52	29224920	N-METHYL TAURINE	0.08	0.19	138.48	0.08	0.19	138.26
53	29225011	PARA-AMINO-SALICYLIC ACID	0.00	0.01	######	0.00	0.01	3,496.10
54	29225013	PROCAINE HYDROCHLORIDE	0.02	0.06	199.29	0.02	0.39	1,586.05
55	29225015	L-TYROSINE(P-	0.00	0.01	725.56	0.00	0.01	538.02
56	29225021	FRUSEMIDE	16.05	13.65	-14.90	22.19	22.36	0.78
57	29225024	D0MPERID0NE	8.46	13.10	54.97	19.41	15.70	-19.08
58	29231000	CHOLINE AND ITS SALTS	5.00	3.09	-38.17	12.85	11.97	-6.90
60	29242910	ACETANILIDE	0.03	0.03	10.35	0.37	0.20	-45.73
61	29242960	PYRAZINAMIDE(PYRAZINE	1.29	4.01	210.09	5.08	7.81	53.69
62	29242970	Pretilachlor (ISO)	0.06	6.23	######	0.06	6.66	#######
63	29262000	1-	0.00	0.00	7.21	0.01	0.00	-86.90
66	29280010	ISONIAZID	1.00	2.87	187.93	1.44	3.38	134.52
67	29304000	METHIONINE	0.20	0.30	47.60	0.28	0.91	227.91
69	29322010	COUMARIN, METHYLCOUMARINS AND ETHYLCOUMARINS	9.19	7.22	-21.46	17.33	20.80	20.03
72	29331100	PHENAZONE (ANTIPYRIN) AND ITS DERIVATIVES	15.55	9.34	-39.94	20.94	18.75	-10.49
73	29331910	3-CARBOXY (PARA SLPHPHNYL)-5 PYRAZOLONE	0.63	1.12	78.69	0.86	2.10	144.97
74	29331920	1(2:5 DCHLR-4-SLPHPHNYL)-3-MTHYL-5-PYRAZLN	0.69	0.10	-85.81	1.49	0.79	-46.59
75	29331930	3-MTHYL-1(4-SLPHO-0-TOLUYL-5-PYRAZOLDNE)	1.03	0.12	-88.47	2.06	0.41	-80.00
76	29331940	PHENYL-METHYL PYRAZOLONE	0.00	0.00	######	0.00	0.03	#######
80	29332910	TINIDAZOLE	2.79	2.32	-16.61	6.00	4.93	-17.85
81	29332920	METRONIDAZOLE METRONIDIAZOLE BENZOATE	10.04	12.41	23.67	17.64	26.38	49.57
82	29332930	MEBENDAZOLE	2.29	4.28	86.72	6.66	10.93	64.09
83	29332940	DIMETRIDAZOLE	8.76	2.57	-70.71	27.53	4.00	-85.47
84	29332950	ALBENDAZ0LE	11.64	13.38	14.97	22.25	23.87	7.29
86	29333914	CHLORPHENIRAMINE MALEATE	6.93	2.08	-69.96	12.03	6.25	-48.05
87	29333917	Chlorantraniliprole (ISO)	0.05	0.33	612.45	0.05	0.33	612.45
90	29333929	Other	86.67	85.37	-1.50	186.96	159.69	-14.59
91	29334100	LEVORPHANOL (INN) AND ITS	1.38			2.53		
92	29335200	MALONYLUREA (BARBITURIC ACID) AND ITS SALS	0.00	0.00	-65.79	0.01	0.00	-70.68
93	29335300	ALLOBARBITAL AND OTHR BARBITAL COMPNDS ANDITS	2.45	1.48	-39.35	2.76	2.25	-18.28
94	29335400	OTHER DERIVATIVES OF MALONYLUREA (BARBITURIC	0.56	0.01	-99.07	5.76	0.81	-85.90
95	29335500	LOPRAZOLAM, MECLOQUALONE, METHAQUALONE , ZIPEROL, SALTS						
96	29335910	AMINOPHYLLINE(CORDOPHYLIN)	1.11	0.11	-90.34	1.12	0.84	-25.01
97	29335920	TRIMETHOPRIM	9.38	10.80	15.14	16.31	18.56	13.76
98	29335930	DIETHYL CARBANAZINE CITRATE	0.07			0.07	0.01	-85.30

99	29335940	1 - AMINO-4METHYL PIPERAZINE	0.36	4.24	######	8.23	10.42	26.56
100	29339100	ALPRA ZOLAM, CAMAZEPAM AND OTHER CMPNDS OF ZEPAM, SALTS	10.95	12.51	14.21	25.97	31.37	20.77
101	29339200	AZINPHOS-METHYL (ISO)		0.00		0.01	0.23	1,812.59
103	29349100	AMINOREX, BROTIZOLAM AND OTHER LIKE CMPNDS, SALTS	3.29	18.04	448.03	7.13	19.17	168.74
104	29349200	OTHER FENTANYLS AND THEIT	0.00	4.63	######	0.03	4.63	########
105	29349910	CHIARO THIOPHENE-2-CARBOXYL		0.02		0.00	0.02	3,785.81
106	29349920	MORPHOLINE	5.80	12.52	115.82	12.44	18.20	46.31
107	29349990	OTHER	393.43	413.65	5.14	683.62	905.72	32.49
108	29351000	N-METHYLPERFLUOROOCTANE SULPHONAMIDE	0.38	2.02	434.94	0.38	2.02	434.94
109	29352000	N-ETHYLPERFLUOROOCTANE		0.23			0.35	
110	29355090	Other	1.68	0.49	-71.06	1.69	1.80	6.69
111	29359011	SULPHAMETHOXAZOLE	23.74	23.11	-2.66	41.11	47.90	16.51
112	29359012	SULPHAFURAZOLE				0.03		
113	29359013	SULPHADIAZINE	3.91	6.55	67.78	5.84	10.83	85.40
114	29359014	SULPHADIMIDINE				0.11	0.03	-75.45
118	29362100	VITAMINS A AND THEIR	18.94	14.80	-21.86	33.48	38.99	16.46
119	29362210	VITAMIN B1I(THIAMINE, ANEURINE) AND ITS SALT	4.56	3.40	-25.36	6.56	12.10	84.48
120	29362290	OTHER VITAMIN B1I AND ITS	28.51	2.81	-90.14	33.72	41.12	21.93
121	29362310	VITAMIN B2 (RIBOFLAVIN, LACTOPLAVIN) AND ITS SALTS	8.21	7.48	-8.92	21.37	12.62	-40.93
122	29362390	OTHER VITAMIN B2 AND ITS	0.12	0.00	-97.06	0.16	0.01	-95.88
123	29362400	D-OR DL-PANTOTHENIC ACID (VITAMIN B5) AND ITS	0.22	0.31	38.42	0.60	0.40	-33.62
124	29362500	VITAMIN B6 AND ITS DRVTS	0.07	1.79	######	0.29	1.92	566.00
125	29362610	VITAMIN B12 (CYNOCOBALAMIN)	0.38	1.45	282.19	0.61	1.95	221.28
126	29362690	OTHER VITAMIN B12 AND ITS	0.98	2.85	190.93	4.07	41.87	927.76
127	29362700	VITAMIN C (ASCORBIC ACID) AND	7.08	10.01	41.48	12.07	17.79	47.35
128	29362800	VITAMIN E AND ITS DERIVATIVES	10.96	20.99	91.57	28.16	36.80	30.69
129	29362910	FOLIC ACID (VITAMIN B9)	3.86	6.45	67.37	6.20	9.39	51.57
130	29362920	NCTNC ACID AND NCTNMD(NIACINAMIDE/NIACINE	63.56	55.78	-12.24	110.43	116.04	5.08
131	29362930	VITAMIN K (MENAPHTHONUM	0.40	20.19	######	0.40	25.24	6,212.66
132	29362940	VITAMIN D	7.08	22.11	212.36	16.79	53.08	216.14
133	29362950	VITAMIN H (BI0LIN)	0.50	0.02	-96.77	0.80	0.07	-91.33
134	29362990	OTHER VITAMINS AND THR	14.35	11.41	-20.53	23.92	28.06	17.30
135	29369000	OTHER, INCL. NATURAL	23.46	41.77	78.01	48.21	77.17	60.07
136	29371100	SOMATOTROPIN, ITS DRVTVSAND STRCTL ANALOGVES	0.00			0.74		
137	29371200	INSULIN AND ITS SALTS	23.66	24.86	5.06	29.43	30.76	4.54
138	29371900	OTHER POLYPEPTIDE HORMONES THR DTVTVS AND STRCTL ANLGES	15.28	17.86	16.90	21.81	36.00	65.06
139	29372100	DNISONE (DEHY-DROCORTISONE)AND FREDNISOLONE AND	10.78	13.17	22.11	20.40	20.19	-1.06
140	29372200	HALGNTD DRVTVS OF CORTI	27.86	20.05	-28.04	41.24	38.18	-7.41
141	29372300	OESTROGENS AND PROGESTOGENS	17.72	4.19	-76.34	29.50	10.84	-63.26

142	29372900	OTHR STEROIDAL HORMONS THR DRVTVS AND STRCTL ANLGES	67.42	96.11	42.56	139.97	157.59	12.59
143	29375000	TIROMBOXAMESAND LEUKOTRIENESTHR DRVTVS AND STRCLT ANLGES	0.25	0.07	-73.91	0.59	0.42	-28.76
144	29379011	EPINETHRINE						
145	29379019	OTHER	0.01	1.43	######	0.81	1.43	74.88
146	29379020	AMINO-ACID DERIVATIVES	26.07	1.24	-95.24	36.16	9.09	-74.86
147	29379090	OTHER	11.56	11.64	0.64	44.76	19.59	-56.24
148	29381000	RUTOSIDE (RUTIN) AND ITS	0.00	0.00	######	0.01	0.01	-34.43
149	29389010	DIGOXIN	0.65	0.68	4.16	0.82	1.69	106.38
150	29389090	OTHER GLYCOSIDES NTRL/RPRDCD BY SYNTHSIS ANDTHR SLTS ETHRS	49.49	63.71	28.73	81.88	109.74	34.02
151	29391100	CMPNDS OF MORPHIN, CODEINE, CODONE, THE BAINE, SALTS THEREOF		1.12		0.00	1.12	
152	29392010	QUININE ALKALOIDS					0.00	
153	29392020	QUININE HYDROCHLORIDE	1.09	2.38	118.45	2.69	5.15	91.32
154	29392030	QUININE SULPHATE	0.02	0.97	######	1.08	1.27	18.31
155	29392040	CHL0R0QUINE PH0SPHATE	1.27	2.27	79.21	1.99	4.88	144.89
156	29393000	CAFFEINE AND ITS SALTS	38.77	52.34	35.01	77.21	90.25	16.88
157	29394100	(ALKALOIDS OF EPHEDRA AND THEIR DERIVATIVES; SALTS THEIR OF)	0.65	3.61	457.49	3.01	5.36	78.43
158	29394300	(ALKALOIDS OF EPHEDRA AND THEIR DERIVATIVES; SALTS THEIR OF)						
159	29394400	(ALKALOIDS OF EPHEDRA AND THEIR DERIVATIVES; SALTS THEIR OF)	0.05	2.73	######	0.14	2.73	1,904.75
160	29394900	OTHER	1.74	0.04	-97.77	2.98	1.35	-54.75
161	29395100	FENETYLLINE (INN) AND ITS SALTS						
162	29395900	OTHER THEOPHYLLINE AND AMINOPHYLLINE THR DRVTVS,	34.13	31.64	-7.31	57.09	64.57	13.11
163	29396290	OTHER ERGOTAMINE SALTS						
164	29396900	OTHER, OF VEGETAL ORIGIN	1.34	2.04	51.66	3.47	2.04	-41.22
165	29397900	OTHER	109.98	162.96	48.18	173.44	252.82	45.77
166	29398000	OTHER	13.96	4.09	-70.69	31.06	10.84	-65.11
167	29411010	PENICILLINS AND ITS SALTS	0.12			0.12	0.00	-99.90
168	29411020	AMPICILLINE AND ITS SALTS	22.27	11.97	-46.26	39.90	38.72	-2.96
169	29411030	AMOXYCILLINE AND ITS SALTS	127.31	84.28	-33.80	239.66	195.73	-18.33
170	29411040	CLOXACILLINE AND ITS SALTS	19.57	17.16	-12.31	27.12	24.46	-9.81
171	29411050	6 - APA						
172	29411090	OTHER PENICILLINS AND THR DRVTVS WTH A PENTCILLIANIC	41.29	54.36	31.66	75.55	116.50	54.20
173	29412010	STREPTOMYCINS		0.00		0.04	0.01	-65.72
174	29412090	OTHER STREPTOMYCINE AND	0.06	0.01	-85.46	0.06	0.01	-78.30
175	29413010	DOXYCYLIME AND ITS SALTS	0.01	1.55	######	1.89	1.55	-18.22
176	29413020	TETRACYCLINE/OXYTETRA - CYCLINE AND HR SALTS	0.67	0.52	-21.78	5.65	2.21	-60.94

177	29413090	OTHER TETRACYCLINES AND THR	0.06	0.01	-83.94	0.20	0.18	-10.39
178	29414000	CHLORAMPHENICOL AND ITS DRVTVS SLTS THEREOF	1.02	3.21	214.94	2.22	6.18	178.15
179	29415000	ERTHROMYCIN AND ITS DRVTVS	78.43	70.55	-10.05	140.82	144.65	2.72
180	29419011	RIFAMPICIN	11.55	12.59	9.03	22.91	31.14	35.93
181	29419013	RIFA OR RIFA S SODIUM (RIFAINT)						
182	29419019	OTHER RIFAMPICIN AND ITS SALTS	1.52	3.07	101.80	3.78	3.51	-7.11
183	29419020	CEPHALEXIN AND ITS SALTS	4.13	2.16	-47.79	12.17	3.72	-69.42
184	29419030	CIPROFLOXACINE AND ITS SALTS	17.68	17.15	-3.00	28.13	29.73	5.68
185	29419040	GENTAMYCIN AND ITS SALTS	0.12	0.01	-92.89	0.12	0.01	-91.74
186	29419050	NEOMYCIN	0.00	0.01	340.57	0.01	0.03	544.79
187	29419060	NORFLOXACIN AND ITS SALTS	0.91	1.00	10.13	1.94	4.13	113.54
188	29419090	OTHER ANTIBIOTICS	392.72	292.16	-25.61	807.26	566.60	-29.81
189	29420011	CEFADROXIL	14.69	9.49	-35.41	51.20	21.95	-57.13
190	29420012	IBUPROFANE	66.49	43.92	-33.95	123.52	101.55	-17.79
191	29420013	NIFEDIPINE	0.86	2.91	239.72	1.39	4.80	246.30
192	29420014	RANITIDINE	6.40	6.40	-0.05	13.12	9.11	-30.52
193	29420015	DANES SALT OF D (-) PHENYL						
194	29420016	D(-) PARA HYDROXY DANES SALTS		0.00			0.00	
195	29420021	TIMOLOL MALEATE	8.06	3.97	-50.74	9.83	7.78	-20.83
196	29420022	TERBUTOLINE SULPHATE	0.64	1.12	75.27	1.56	1.34	-14.43
197	29420023	D(-) PHENYL GLYCIN CHLORIDE HCL						
198	29420024	IMIPRAMINE HCL	0.21	1.35	543.42	0.33	1.41	330.46
199	29420025	AMITRYPTYLINE HCL	3.46	4.61	33.27	8.19	8.50	3.87
200	29420026	CYSTEANUNE HCL						
201	29420027	ATENOLOL, PROPRONALOL	7.38	10.64	44.14	13.69	18.44	34.64
202	29420031	DILOXANIDE FUROATE	0.21	0.62	196.34	0.93	0.82	-11.31
203	29420032	CIMETIDINE						
204	29420033	OXYCLOZANIDE	3.16	6.26	98.04	7.17	11.88	65.65
205	29420034	FAMOTIDINE	8.40	11.67	38.94	17.34	18.44	6.36
206	29420090	OTHER DILOXANIDE FUROATE, CIMETIDINE, FAMOTIDINE NES	689.82	730.92	5.96	#####	######	4.40
207	30034100	CONTAINING EPHEDRINE OR ITS		3.70			10.83	
208	30034900	OTHER	0.00	1.00	######	0.01	1.00	7,119.83
209	30036000	ANTIMALARIAL ACTIVE PRINCIPLES DESCRIBED IN SUB HEADING NOTE 2 OF CHAPTER 30				0.60	0.34	-43.84
210	30044100	CONTAINING EPHEDRINE OR ITS	0.00	0.40	######	2.70	0.42	-84.27
211	30044200	CONTAINING PSEUDOEPHEDRINE (INN) OR ITS SALTS						
212	30044300	CONTAINING NOREPHEDRINE OR		0.08			0.08	
213	30044910	ATROPIN AND SALTS THEREOF	3.23	0.78	-75.79	4.72	4.84	2.43
214	30044920	CAFFEIN AND SALTS THEREOF	1.24	1.13	-8.83	4.03	2.47	-38.80
215	30044930	CODEINE AND DERIVATIVES, WITH OR WITHOUT EPHIDRINE	9.18	10.60	15.42	20.17	10.60	-47.44
216	30044940	ERGOT PREPARATIONS, ERGOTAMINE AND SALTS THEREOF	0.03	0.53	######	0.03	0.53	1,873.43
217	30044950	PAPAVARINE HYDROCHLORIDE	0.00	0.03	######	0.03	0.05	60.84
218	30044960	BROMOHEXIN AND SOLBUTAMOL	0.76	1.92	150.95	2.91	3.76	29.19
219	30044970	THEOPHYLLINE AND SALTS		0.03			0.57	

220	30044990	OTHER	4.09	7.22	76.42	7.16	13.78	92.51
221	96020030	GELATIN CAPSULES,EMPTY	57.76	60.24	4.29	124.37	112.74	-9.35
		India's Total Export of BULK	**3155**	**3281.1**	**3.99**	**6063**	**6485.2**	**6.97**

BULK DRUG IMPORTS FOR THE MONTH OF MAY 2025

S.No.	HSCode	Commodity	May-2024 (F)	May-2025 (F)	%Growth	Apr-May2024 (F)	Apr-May2025 (F)	%Growth
1	17023010	GLUCOSE LIQUID		0.00		0.08	0.01	-91.83
2	17023020	GLUCOSE SOLID	0.92	0.85	-7.84	1.74	1.96	12.88
3	17023031	DEXTROSE,SOLID		0.09		0.17	1.33	700.25
4	17023039	DEXTROSE OTHER THAN SOLID	0.81	0.95	16.97	1.55	1.23	-20.70
5	29051410	ETHAMBUTOL, ETHAMBUTOL HCL	4.17	7.70	84.37	5.43	10.30	89.69
6	29051420	SALBUTAMOL SULPHATE	0.45	0.20	-55.48	0.45	0.69	52.29
7	29054300	MANNITOL	35.67	62.51	75.24	67.08	99.33	48.08
8	29054400	D-GLUCITOL (SORBITOL)	9.85	8.40	-14.74	15.26	14.87	-2.57
9	29071930	THYMOL	0.07	0.34	370.19	0.25	0.35	39.75
10	29072200	HYDROQUINONE (QUINOL) AND ITS SALTS	31.85	33.66	5.68	60.75	54.43	-10.41
11	29095010	GUAIACOL	1.81	2.22	22.91	2.42	2.79	15.42
12	29124940	3,4,5-TRIMETHOXY-BENZALDEHYEDE	0.65			1.31	0.70	-46.13
13	29154010	MONOCHLOROACETIC ACID,THR SALTS AND ESTERS	4.72	0.83	-82.40	9.70	1.65	-82.97
14	29163120	BENZYL BENZOATE	0.10	0.83	776.44	0.59	0.86	44.46
15	29163150	BENZOCAINE (ETHYLPARA-AMINO BENZOATE)	0.01	0.02	269.30	0.01	0.10	1,663
16	29163400	PHENYLACETIC ACID AND ITS SALTS	7.57			14.37		
17	29171940	FERROUS FUMERATE	0.08	0.30	254.99	0.15	0.30	95.46
18	29171970	ETH0XY METHYLENE MAL0NATE,DIETHYL MAL0NATE	16.28	10.76	-33.89	27.90	21.71	-22.18
19	29181120	CALCIUM LACTATE	0.06	0.11	90.96	1.06	0.22	-79.44
20	29181320	METROPROLOL TARTRATE		1.89			5.61	
21	29181510	POTASSIUM CITRATE	1.79	1.12	-37.24	2.46	1.12	-54.34
22	29181520	SODIUM CITRATE	2.14	0.51	-76.18	4.44	4.91	10.76
23	29181610	CALCIUM GLUCONATE	8.47	7.17	-15.37	14.35	14.16	-1.37
24	29182110	SALICYLIC ACID	22.94	14.02	-38.86	45.62	33.71	-26.12
25	29182120	SODIUM SALICYLATE	0.18	0.31	72.26	0.18	0.32	76.94
26	29182200	0-ACETYLSALICYLIC ACID ITS SALTS AND ESTRS	0.00	0.24	18,476	0.12	0.24	101.94
27	29182310	METHYL SALICYLATE	1.01	0.25	-75.47	1.81	0.61	-66.14
28	29183030	NALIDIXIC ACID	1.98	0.67	-66.29	3.95	0.67	-83.09
29	29214236	METHYL DOPA(L-ALPHA METHYL-3, 4-DIHYDROXYPHENYLALANINE)	15.04	12.31	-18.13	18.90	14.25	-24.62
30	29214600	AMFETAMINE BENZFETAMINE ETC THR SALTS	0.86	0.63	-26.69	1.16	0.63	-45.82
31	29215110	O- PHENYLENEDIAMINE	19.21	9.96	-48.16	28.14	25.63	-8.89

32	29215120	M-PHENYLENEDIAMINE (M-DIAMINOBENZENE)	2.33	2.02	-13.34	7.05	4.40	-37.60
33	29215130	P-PHENYLENEDIAMINE	3.40	1.09	-67.95	9.28	7.48	-19.39
34	29223100	AMFEPRA NONE(INN), METHDONE AND MORMETHADONESALTS						
35	29224100	LYSINE AND ITS ESTERS SALTS THEREOF	105.72	73.40	-30.57	189.33	181.02	-4.39
36	29224210	GLUTAMIC ACID	0.34	0.01	-98.48	1.67	0.35	-79.30
37	29224220	MONOSODIUM GLUTAMATE (AZINAMOTO)	42.60	57.16	34.19	79.00	96.24	21.82
38	29224910	AMINO ACETIC ACID (GLYCINE)	20.98	17.65	-15.86	37.70	30.70	-18.57
39	29224920	N-METHYL TAURINE	0.09	4.38	4,594.00	0.09	6.39	6,750
40	29225011	PARA-AMINO-SALICYLIC ACID		0.01			0.03	
41	29225015	L-TYROSINE(P-HYDROXYPHENYLAMINE)	1.46	2.42	65.87	1.63	5.62	245.42
42	29231000	CHOLINE AND ITS SALTS	2.20	2.19	-0.43	6.83	3.40	-50.27
43	29241100	MEPROBAMATE (INN)	0.10	0.68	575.83	3.88	2.56	-34.05
44	29242910	ACETANILIDE	10.19	19.53	91.72	33.06	32.68	-1.14
45	29242960	PYRAZINAMIDE(PYRAZINE CARBOXAMIDE)	0.80	0.97	20.68	0.81	1.01	24.48
46	29242970	Pretilachlor (ISO)	0.06	1.68	2,811.52	0.07	2.65	3,551
47	29262000	1-CYANOGUANIDINE(DICYANDIAMIDE)	54.69	50.97	-6.81	87.79	94.18	7.28
48	29263000	FENPROPOREX (INN) AND ITS SALTS		6.88			6.88	
49	29264000	ALPHA-PHENYLACETOACETONITRILE	0.04	1.11	2,740.54	0.11	1.23	975.26
50	29280010	ISONIAZID	1.72			1.72	10.78	526.78
51	29304000	METHIONINE	129.55	87.56	-32.41	250.37	216.40	-13.57
52	29309040	L-CYSTINE (ALPHA-AMINO BETA-THIO PROPIONICACID)-SULPHUR CONTAINING AMINO ACID	11.67			20.79		
53	29322010	COUMARIN, METHYLCOUMARINS AND ETHYLCOUMARINS	0.84	0.00	-99.91	0.88	0.00	-99.61
54	29329300	PIPERAN0L	1.07	1.94	81.27	3.75	3.99	6.63
55	29331100	PHENAZONE (ANTIPYRIN) AND ITS DERIVATIVES	1.13	2.40	112.10	2.51	3.42	36.20
56	29331910	3-CARBOXY (PARA SLPHPHNYL)-5 PYRAZOLONE				1.06	0.45	-57.30
57	29331920	1(2:5 DCHLR-4-SLPHPHNYL)-3-MTHYL-5-PYRAZLN				0.26	1.03	288.49
58	29331940	PHENYL-METHYL PYRAZOLONE	0.28	0.98	254.14	1.29	1.24	-3.36
59	29331970	ANALGIN	2.94	2.95	0.60	4.61	4.76	3.19

60	29331980	0XYPHENBUTAZONE				0.11		
61	29332910	TINIDAZOLE	0.06	0.41	542.35	0.07	0.41	470.59
62	29332920	METRONIDAZOLE METRONIDIAZOLE BENZOATE	12.38	9.76	-21.12	16.38	15.56	-4.99
63	29332950	ALBENDAZ0LE	0.66	2.18	230.09	1.20	2.18	81.67
64	29333929	Other	15.03	9.19	-38.87	29.96	22.69	-24.24
65	29334100	LEVORPHANOL (INN) AND ITS SALTS						
66	29335200	MALONYLUREA (BARBITURIC ACID) AND ITS SALS	6.07	4.94	-18.69	6.98	7.43	6.42
67	29335300	ALLOBARBITAL AND OTHR BARBITAL COMPNDS ANDITS SALTS	0.00			0.00	0.20	4,561
68	29335400	OTHER DERIVATIVES OF MALONYLUREA (BARBITURIC ACID), SALTS THEREOF		2.85			3.27	
69	29335910	AMINOPHYLLINE(CORDOPHYLIN)	1.48			1.48	0.05	-96.69
70	29335920	TRIMETHOPRIM	0.34	1.01	201.31	0.42	1.38	228.82
71	29339100	ALPRA ZOLAM, CAMAZEPAM AND OTHER CMPNDS OF ZEPAM, SALTS THEREOF	6.47	1.49	-77.04	7.23	2.00	-72.38
72	29339200	AZINPHOS-METHYL (ISO)					0.00	
73	29349100	AMINOREX, BROTIZOLAM AND OTHER LIKE CMPNDS, SALTS THEREOF				0.01		
74	29349200	OTHER FENTANYLS AND THEIT DERIVATIVES		0.54		0.77	0.54	-30.38
75	29349910	CHIARO THIOPHENE-2-CARBOXYL IC ACID	0.30	0.41	38.75	0.56	0.89	58.19
76	29349920	MORPHOLINE	6.35	0.31	-95.15	12.30	3.41	-72.26
77	29349990	OTHER	590.39	466.21	-21.03	1,017	948.97	-6.70
78	29353000	N-ETHYL-N-(2-HYDROXYETHYL) PERFLUOROOCTANE SULPHONAMIDE				0.02	0.00	-92.18
79	29355090	Other		0.09		0.02	0.22	1,002
80	29359011	SULPHAMETHOXAZOLE		0.01		0.20	0.04	-82.23
81	29359013	SULPHADIAZINE	0.49	1.06	115.71	0.73	1.21	65.13
82	29359014	SULPHADIMIDINE	0.38	2.04	430.67	1.54	3.69	140.31
83	29362100	VITAMINS A AND THEIR DERIVATIVES	10.66	10.68	0.13	21.04	24.94	18.54
84	29362210	VITAMIN B1I(THIAMINE, ANEURINE) AND ITS SALT	5.28	27.11	413.84	7.17	43.86	511.81
85	29362290	OTHER VITAMIN B1I AND ITS DRIVATIVES	0.72	3.60	399.05	2.63	5.70	116.76
86	29362310	VITAMIN B2 (RIBOFLAVIN, LACTOPLAVIN) AND ITS SALTS	11.92	8.79	-26.31	23.72	12.64	-46.71

87	29362390	OTHER VITAMIN B2 AND ITS DERIVATIVES	7.19	3.95	-45.01	11.42	4.95	-56.69
88	29362400	D-OR DL-PANTOTHENIC ACID (VITAMIN B5) AND ITS DERIVATIVES	6.54	5.93	-9.36	9.94	10.08	1.37
89	29362500	VITAMIN B6 AND ITS DRVTS	13.52	6.56	-51.50	22.79	11.33	-50.30
90	29362610	VITAMIN B12 (CYNOCOBALAMIN)	7.38	22.94	210.66	17.85	49.96	179.92
91	29362690	OTHER VITAMIN B12 AND ITS DERIVATIVES	0.11	4.94	4,580.76	1.38	6.60	378.75
92	29362700	VITAMIN C (ASCORBIC ACID) AND ITS DRVTVS	6.85	19.90	190.59	16.10	40.89	153.95
93	29362800	VITAMIN E AND ITS DERIVATIVES	40.39	25.99	-35.66	66.15	55.31	-16.39
94	29362910	FOLIC ACID (VITAMIN B9)	2.94	6.57	123.56	5.15	8.25	60.02
95	29362920	NCTNC ACID AND NCTNMD(NIACINAMIDE/NIACINE	0.14	0.97	596.02	0.82	1.10	33.14
96	29362930	VITAMIN K (MENAPHTHONUM B.P.)	1.19	0.36	-69.84	3.05	1.15	-62.33
97	29362940	VITAMIN D	19.28	15.76	-18.28	23.33	25.54	9.46
98	29362950	VITAMIN H (BI0LIN)	1.12	0.60	-47.00	3.55	1.19	-66.40
99	29362990	OTHER VITAMINS AND THR DRVTVS	15.05	7.33	-51.31	23.61	13.14	-44.35
100	29369000	OTHER, INCL. NATURAL CONCENTRTS	0.11	1.11	875.50	0.83	1.97	137.17
101	29371100	SOMATOTROPIN, ITS DRVTVSAND STRCTL ANALOGVES	0.00			0.00	0.01	196.44
102	29371200	INSULIN AND ITS SALTS	46.00	71.76	56.02	68.99	110.96	60.84
103	29371900	OTHER POLYPEPTIDE HORMONES THR DTVTVS AND STRCTL ANLGES	32.31	28.09	-13.08	65.33	61.08	-6.50
104	29372100	CORTISONE,HYDROCORTISONE ,PREDNISONE (DEHY-DROCORTISONE)AND FREDNISOLONE AND PRDNSLN(DEHYDROHYDROCORTISONE)	35.86	31.00	-13.55	67.85	57.61	-15.08
105	29372200	HALGNTD DRVTVS OF CORTI COSTEROIDAL	28.79	21.55	-25.14	40.20	51.26	27.51
106	29372300	OESTROGENS AND PROGESTOGENS	41.56	46.61	12.16	87.29	98.78	13.17
107	29372900	OTHR STEROIDAL HORMONS THR DRVTVS AND STRCTL ANLGES	115.82	74.01	-36.10	186.41	134.21	-28.01
108	29375000	PROSTAGLANDINS, TIROMBOXAMESAND LEUKOTRIENESTHR DRVTVS AND STRCLT ANLGES	6.73	1.42	-78.86	13.72	3.30	-75.94

109	29379011	EPINETHRINE		0.03			0.03	
110	29379019	OTHER	7.32	1.75	-76.10	16.37	4.39	-73.17
111	29379020	AMINO-ACID DERIVATIVES	5.57	3.64	-34.69	10.60	8.11	-23.52
112	29379090	OTHER	46.46	41.93	-9.74	94.21	77.38	-17.87
113	29381000	RUTOSIDE (RUTIN) AND ITS DERIVATIVES	1.16	4.27	269.65	1.45	6.33	337.27
114	29389090	OTHER GLYCOSIDES NTRL/RPRDCD BY SYNTHSIS ANDTHR SLTS ETHRS DRVTVS	111.32	33.02	-70.34	145.19	94.38	-34.99
115	29391100	CONCENTRATES OF POPPY STRAW CMPNDS OF MORPHIN, CODEINE, CODONE, THE BAINE, SALTS THEREOF	7.89	0.28	-96.41	15.75	0.29	-98.14
116	29392010	QUININE ALKALOIDS	0.78	0.53	-32.34	1.56	0.89	-42.97
117	29392030	QUININE SULPHATE	0.08	0.45	429.09	0.08	0.45	429.09
118	29393000	CAFFEINE AND ITS SALTS	15.77	17.70	12.28	28.66	55.83	94.79
119	29394100	EPHEDRINE AND ITS SALTS (ALKALOIDS OF EPHEDRA AND THEIR DERIVATIVES; SALTS THEIR OF)				0.01	0.29	3,615
120	29394400	NOREPHEDRINE AND ITS SALTS (ALKALOIDS OF EPHEDRA AND THEIR DERIVATIVES; SALTS THEIR OF)	0.01			0.01		
121	29395900	OTHER THEOPHYLLINE AND AMINOPHYLLINE THR DRVTVS, SALTS	1.52	2.42	59.18	2.09	2.71	29.89
122	29396300	LYSERGIC ACID AND ITS SALTS						
123	29396900	OTHER, OF VEGETAL ORIGIN	1.49	0.41	-72.27	5.91	2.01	-66.01
124	29397200	COCAINE, ECGONINE; SALTS, ESTERS AND OTHER DERIVATIVES THEREOF						
125	29397900	OTHER	1.28	3.89	205.15	3.97	11.17	181.12
126	29398000	OTHER	8.25	0.91	-89.02	39.92	5.83	-85.39
127	29411010	PENICILLINS AND ITS SALTS	129.10	93.65	-27.46	344.35	139.48	-59.49
128	29411020	AMPICILLINE AND ITS SALTS	0.00	0.00	147.04	0.01	0.00	-19.72
129	29411030	AMOXYCILLINE AND ITS SALTS	31.69	29.55	-6.77	78.93	50.14	-36.47
130	29411040	CLOXACILLINE AND ITS SALTS		3.36			3.36	
131	29411050	6 - APA	249.71	282.60	13.17	632.21	583.13	-7.76
132	29411090	OTHER PENICILLINS AND THR DRVTVS WTH A PENTCILLIANIC ACID STRCTR SLTS THEREOF	30.96	82.50	166.47	117.62	141.94	20.67
133	29412010	STREPTOMYCINS	0.53	2.02	280.90	1.97	7.96	304.86
134	29412090	OTHER STREPTOMYCINE AND DRVTVS, SALTS	2.87	0.11	-96.19	3.03	2.51	-17.38

135	29413010	DOXYCYLIME AND ITS SALTS	15.51	29.33	89.03	31.84	40.01	25.66
136	29413020	TETRACYCLINE/OXYTETRA - CYCLINE AND HR SALTS	9.63	11.83	22.76	14.17	16.81	18.63
137	29413090	OTHER TETRACYCLINES AND THR DRVTVS SLTS	17.71	27.16	53.34	35.64	28.53	-19.96
138	29414000	CHLORAMPHENICOL AND ITS DRVTVS SLTS THEREOF	1.21	0.01	-98.98	4.68	0.45	-90.48
139	29415000	ERTHROMYCIN AND ITS DRVTVS SLTS THEREOF	157.97	145.05	-8.18	233.94	288.59	23.36
140	29419011	RIFAMPICIN	17.34	66.71	284.67	57.32	126.80	121.22
141	29419013	RIFA OR RIFA S SODIUM (RIFAINT)	13.75	24.51	78.26	16.66	48.08	188.59
142	29419014	1 - AMINO -4 - METHYL PIPERAZINE (RIFAINT)	0.62			0.62		
143	29419019	OTHER RIFAMPICIN AND ITS SALTS	22.60	38.25	69.21	72.97	84.40	15.67
144	29419020	CEPHALEXIN AND ITS SALTS	28.03	18.80	-32.93	40.81	29.29	-28.22
145	29419030	CIPROFLOXACINE AND ITS SALTS	11.69	2.95	-74.80	17.66	7.06	-60.03
146	29419040	GENTAMYCIN AND ITS SALTS	4.25	6.89	62.05	6.45	9.60	48.84
147	29419060	NORFLOXACIN AND ITS SALTS	2.97	0.02	-99.45	20.67	0.40	-98.08
148	29420011	CEFADROXIL	2.36	0.00	-99.99	2.36	0.00	-99.99
149	29420012	IBUPROFANE	7.03	11.91	69.49	7.04	15.29	116.98
150	29420013	NIFEDIPINE	0.08			0.08		
151	29420014	RANITIDINE		1.61			1.61	
152	29420015	DANES SALT OF D (-) PHENYL GLYCINE	14.82	15.07	1.73	39.00	26.07	-33.16
153	29420016	D(-) PARA HYDROXY DANES SALTS	27.08	7.11	-73.74	46.65	11.12	-76.15
154	29420021	TIMOLOL MALEATE	0.64	0.01	-99.17	0.65	1.13	74.66
155	29420022	TERBUTOLINE SULPHATE		0.04			0.04	
156	29420023	D(-) PHENYL GLYCIN CHLORIDE HCL (DPGCH)		0.18			0.18	
157	29420026	CYSTEANUNE HCL	2.43	3.50	44.28	2.68	4.68	74.69
158	29420027	ATENOLOL, PROPRONALOL	7.30			8.11		
159	29420032	CIMETIDINE	0.33			0.33	0.28	-15.16
160	29420034	FAMOTIDINE	0.39			0.97	0.54	-44.12
161	29420090	OTHER DILOXANIDE FUROATE, CIMETIDINE, FAMOTIDINE NES	198.95	270.50	35.97	410.20	510.61	24.48
162	30034900	OTHER				0.07		
163	30044200	CONTAINING PSEUDOEPHEDRINE (INN) OR ITS SALTS		0.01			0.01	
164	30044990	OTHER	5.79	3.94	-32.03	16.35	9.54	-41.67
165	96020030	GELATIN CAPSULES,EMPTY	4.73	2.10	-55.74	11.18	3.60	-67.82
		India's Total Import of BULK DRUGS	**3447**	**3301.5**	**-4.23**	**6586.25**	**6434.2**	**-2.31**

Important Note:

The organizers of Global ChemiShow offered 30 stalls (fully furnished 9 sq. meter stalls) on Complimentary basis. 12 of our members have already taken the Stalls. Members who are interested to avail these FREE stalls, please write to ed@bdmai.org ; info@bdmai.org; Stalls will be allotted on first-come-first-serve basis.